Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02657889 · ClinicalTrials.gov registry record · Phase 1
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
A Phase 1 study, sponsored by Tesaro.
- Completed
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT02657889 is a Phase 1 study that has completed, run by Tesaro. The registered enrollment target is 122 participants.
The verdict
NCT02657889, a Phase 1 study, has completed, sponsored by Tesaro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
Interventions
- BIOLOGICAL pembrolizumab
- DRUG niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2016-04-15 |
| Est. Completion | 2021-09-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02657889
The ClinicalTrials.gov registry entry for NCT02657889 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tesaro, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT02657889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02657889 about?
NCT02657889 is a clinical study titled "Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer". This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (KEYNOTE-162)
What is the current status of trial NCT02657889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2016-04-15. Estimated completion is 2021-09-17.
What interventions are being tested in trial NCT02657889?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), niraparib (DRUG).
Who is sponsoring clinical trial NCT02657889?
This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.